Ideaya Biosciences price target lowered to $63 from $65 at Truist
Truist analyst Gregory Renza lowered the firm's price target on Ideaya Biosciences to $63 from $65 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, w